RxDoctor Payments Data

Linda Pham

Adult Health · Stoneham, MANPI 1871064170

Payments from drug & device makers

$1,286in general payments, 2019–2025

Across 46 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • Johnson & Johnson$158
  • Amgen$124
  • Strata Skin Sciences, Inc.$100
  • Regeneron Healthcare Solutions, Inc.$96
  • Sun Pharmaceutical Industries Inc.$89
  • plus $510 from 11 others

What the payments were for

  • Food & beverage$1,21995%
  • Education$675%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,286 in reported general payments places this provider in the 80th percentile of 671 adult health providers in Massachusetts.

See all adult health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$135,325
Medicare patients
505
Services billed
4,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast25$100,471
Dupixent PenDupilumab23$93,628
VtamaTapinarof11$15,498
Clobetasol Propionate47$3,055
Tacrolimus25$2,759
Fluorouracil52$2,732
Ketoconazole99$1,785
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc44$1,733
Tretinoin15$1,218
Clindamycin Phosphate26$1,068
Metronidazole17$851
Betamethasone Dipropionate16$805
Triamcinolone Acetonide74$678
Mupirocin31$205
ValacyclovirValacyclovir Hcl14$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$124$100,47125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 671 adult health providers in Massachusetts.

Other adult health in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →